PepGen: Maintaining 'Hold,' PGN-EDODM1 Data Is A Major Inflection Point
PepGen stays a hold, after a major problem with its released data from the phase 2 FREEDOM2-DM1 study using the PGN-EDODM1 study. Read more on PEPG stock here. - PepGen remains a "Hold" after mixed phase 2 MAD data for PGN-EDODM1 in DM1, with a…